Aminolevulinic acid - Medac

Drug Profile

Aminolevulinic acid - Medac

Alternative Names: 5-ALA - Medac; 5-ALA - Photonamic; 5-ALA Patch; Alacare; Aminolevulinic acid HCl; Effala; Gleolan; Gliolan; PD P 506 A; PD P 506 A-PDT

Latest Information Update: 13 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Photonamic
  • Developer LINK Healthcare; Medac; NX Development Corp; Photonamic; Specialised Therapeutics Australia; Spirig Pharma
  • Class Amino acids; Antineoplastics; Keto acids; Levulinic acids; Oxidants; Skin disorder therapies; Small molecules
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Actinic keratosis; Glioma
  • Phase II Onychomycosis

Most Recent Events

  • 08 Jun 2017 Registered for Glioma (Diagnosis) in USA (PO)
  • 01 Jun 2017 Aminolevulinic acid - Medac receives Fast Track designation for Glioma [PO,Powder] (Diagnosis) in USA before June 2017 (NX Development Corp website, June 2017)
  • 10 May 2017 Registered for Glioma (Diagnosis) in Kuwait, Ukraine, Hong Kong and Israel (PO) before May 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top